Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 5 studies | 23% ± 7% | |
epithelial cell | 5 studies | 33% ± 13% | |
natural killer cell | 4 studies | 25% ± 11% | |
macrophage | 4 studies | 20% ± 4% | |
classical monocyte | 3 studies | 25% ± 7% | |
conventional dendritic cell | 3 studies | 27% ± 9% | |
non-classical monocyte | 3 studies | 29% ± 9% | |
ciliated cell | 3 studies | 24% ± 2% | |
dendritic cell | 3 studies | 30% ± 15% | |
enterocyte | 3 studies | 18% ± 1% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
adrenal gland | 100% | 1709.50 | 258 / 258 | 100% | 38.85 | 230 / 230 |
esophagus | 100% | 1213.63 | 1445 / 1445 | 100% | 15.41 | 183 / 183 |
ovary | 100% | 1286.43 | 180 / 180 | 100% | 26.62 | 430 / 430 |
thymus | 100% | 1501.08 | 653 / 653 | 100% | 27.32 | 603 / 605 |
brain | 100% | 2007.20 | 2635 / 2642 | 100% | 17.86 | 704 / 705 |
uterus | 100% | 1218.25 | 170 / 170 | 99% | 16.72 | 456 / 459 |
liver | 100% | 871.03 | 226 / 226 | 99% | 16.16 | 402 / 406 |
stomach | 100% | 1236.61 | 359 / 359 | 99% | 21.23 | 283 / 286 |
prostate | 100% | 1501.30 | 244 / 245 | 99% | 22.97 | 498 / 502 |
kidney | 100% | 1663.01 | 89 / 89 | 98% | 16.33 | 884 / 901 |
intestine | 100% | 1613.24 | 966 / 966 | 98% | 22.77 | 517 / 527 |
bladder | 100% | 1241.71 | 21 / 21 | 98% | 19.30 | 494 / 504 |
skin | 100% | 1003.10 | 1808 / 1809 | 97% | 12.59 | 457 / 472 |
lung | 99% | 1197.78 | 574 / 578 | 97% | 13.80 | 1117 / 1155 |
pancreas | 100% | 1001.46 | 328 / 328 | 94% | 20.33 | 167 / 178 |
breast | 100% | 1080.21 | 459 / 459 | 90% | 12.43 | 1007 / 1118 |
eye | 0% | 0 | 0 / 0 | 100% | 18.86 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 29.61 | 29 / 29 |
spleen | 100% | 1755.51 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 34.81 | 1 / 1 |
blood vessel | 100% | 1365.78 | 1329 / 1335 | 0% | 0 | 0 / 0 |
adipose | 100% | 1006.83 | 1198 / 1204 | 0% | 0 | 0 / 0 |
heart | 98% | 809.76 | 843 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 13.56 | 44 / 45 |
muscle | 98% | 726.81 | 784 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 97% | 843.31 | 897 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0000086 | Biological process | G2/M transition of mitotic cell cycle |
GO_0016567 | Biological process | protein ubiquitination |
GO_0031146 | Biological process | SCF-dependent proteasomal ubiquitin-dependent protein catabolic process |
GO_0009953 | Biological process | dorsal/ventral pattern formation |
GO_0030282 | Biological process | bone mineralization |
GO_0030513 | Biological process | positive regulation of BMP signaling pathway |
GO_0019005 | Cellular component | SCF ubiquitin ligase complex |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005515 | Molecular function | protein binding |
Gene name | FBXL15 |
Protein name | F-box/LRR-repeat protein 15 F-box/LRR-repeat protein 15 (F-box only protein 37) F-box and leucine rich repeat protein 15 |
Synonyms | FBXO37 |
Description | FUNCTION: Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of SMURF1, thereby acting as a positive regulator of the BMP signaling pathway. Required for dorsal/ventral pattern formation and bone mass maintenance. Also mediates ubiquitination of SMURF2 and WWP2. . |
Accessions | A0A0C4DFV0 ENST00000369956 ENST00000457067.1 X6RHD7 X6RJB2 ENST00000425536.1 Q9H469 ENST00000432590.5 ENST00000369956.8 X6RCZ8 ENST00000440407.5 X6RGT4 |